The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Minimal residual illness, or MRD, testing might have the potential to supply peace of thoughts to survivors of breast most cancers, as a survivor and...
Researchers have introduced data revealing how sufferers with metastatic breast most cancers develop resistance to the therapy Enhertu (trastuzumab deruxtecan, T-DXd) in...
This years 2026 ASCO Gastrointestinal Cancers Symposium was full of practice-shaping knowledge throughout colorectal and higher gastrointestinal malignancies, in line with Dr....
Researchers from the Dana-Farber Most cancers Institute and worldwide analysis teams have revealed information in The New England Journal of Drugs exhibiting...
In an interview with CURE, Dr. Elias Obeid, a medical oncologist at Hackensack College Medical Middle, mentioned the significance of threat evaluation...
